Business
MADRIGAL PHARMACEUTICALS, INC.: We are highly dependent on the success of our only approved product, Rezdiffra.
Revenue increased 432.1% to $958.4M, while Net income increased 38.1% to ($288.3M).
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue $958.4MWatch
- Profitability — Net income ($288.3M)Watch
- Cash generation — Free cash flow ($190.0M)Note
- Accounting — Formula distress score · manipulation flag raised · earnings quality safeWatch
- Insiders — 3 buys; 31 sells in 365 daysOK
- Capital — Comparable payout data unavailableNote
Where the revenue comes from
Fiscal 2025, as MADRIGAL PHARMACEUTICALS, INC. reports it. History and quarterly detail are in the app.
- Reportable$958.4M
Leadership changes
From MADRIGAL PHARMACEUTICALS, INC.'s own filings, the day they're filed.
- Daniel J. Brennan · directors · departureeff. 2026-04-22
- Julian C. Baker · directors · departureeff. 2026-04-22
- Rita Thakkar · President · appointmenteff. 2026-01-12
Latest filings
- 8-K · Company announcement2026-08-12
- 10-Q · Quarterly report2026-07-30
- 8-K · Company announcement2026-07-30
- 8-K · Company announcement2026-06-17
- 10-Q · Quarterly report2026-05-06
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about MADRIGAL PHARMACEUTICALS, INC., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.